Skip to main content

Abstract

Some therapeutic agents used for cancer treatment may significantly interefere with immunohematology testing. Solve it!

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Chapuy CI, Nicholson RT, Aquad MD, Chapuy B, Laubach JP, Richardson PG, et al. Resolving the daratumumab interference with blood compatibility testing. Transfusion. 2015;55(6 Pt 2):1545–54.

    Article  CAS  PubMed  Google Scholar 

  2. DARZALEX® Prescribing Information. Janssen Biotech, Inc., Horsesham, PA. August 2020.

    Google Scholar 

  3. SARCLISA® Prescribing Information. Sanofi-Aventis U.S. LLC, Bridgewater, NJ. March 2021.

    Google Scholar 

  4. Nedelcu E, Hall C, Stoner A, Eichbaum Q, Meena-Leist C. Interference of anti-CD47 therapy with blood bank testing. Transfusion. 2017;57(Suppl S3):148A.

    Google Scholar 

  5. Sher T, Fenton B, Akhtar A, Gertz MA. First report of safety and efficacy of daratumumab in two cases of advanced immunoglobulin light chain amyloidosis. Blood. 2016;128:1987–9.

    Article  CAS  PubMed  Google Scholar 

  6. Bride KL, Vincent TL, Im S-Y, Aplenc R, Barrett DM, Carroll WL, et al. Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia (T-ALL). Blood. 2018;131:995–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Chari A, Arinsburg SA, Jagannath S, Satta T, Treadwell I, Catemero D, et al. Blood transfusion management and transfusion-related outcomes in daratumumab-treated patients with relapsed or refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2018;18(1):44–51. Available from: http://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(17)30111-8/fulltext. Accessed 28 Feb 2022.

    Article  PubMed  Google Scholar 

Further Reading

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Mark T. Friedman .

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Friedman, M.T., West, K.A., Bizargity, P., Annen, K., Gur, H.D., Hilbert, T. (2023). How “Dara” You!. In: Immunohematology, Transfusion Medicine, Hemostasis, and Cellular Therapy. Springer, Cham. https://doi.org/10.1007/978-3-031-14638-1_65

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-14638-1_65

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-14637-4

  • Online ISBN: 978-3-031-14638-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics